Ovid Therapeutics Stock Forward View - Simple Regression
| OVID Stock | USD 2.07 -0.06 -2.82% |
Forecasting Ovid Therapeutics stock price is inherently uncertain, but structured approaches to analyzing market sentiment can improve the odds. This module tracks the noise around Ovid Therapeutics to identify periods where price and perception diverge.
Based on the latest data, the 14-period RSI for Ovid Therapeutics stands at 62, reflecting strengthening positive momentum. This range suggests continued bullish bias without reaching extreme statistical levels.Momentum
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter -0.09 | EPS Estimate Current Year -0.45 | EPS Estimate Next Year -0.37 | Wall Street Target Price 4.049 | EPS Estimate Current Quarter -0.15 |
The hype perspective for Ovid Therapeutics maps headline activity to recent price response and peer coverage. Sentiment context for Ovid Therapeutics is drawn from options positioning and short interest patterns.
Refer to Days Sales Outstanding and Ptb Ratio for expanded analysis.
Ovid Therapeutics Implied Volatility | 1.97 |
For option buyers, high Ovid Therapeutics' implied volatility means paying more for the right to profit from price movements in Ovid Therapeutics. For sellers, elevated implied volatility creates opportunities to collect richer premiums.
The Simple Regression forecasted value of Ovid Therapeutics on the next trading day is expected to be 1.72 with a mean absolute deviation of 0.13 and the sum of the absolute errors of 7.94.Ovid Therapeutics after-hype prediction price | $ 2.07 |
Sentiment metrics here complement forecasting and technical views with analyst and earnings context.
Historical Fundamental Analysis of Ovid Therapeutics can be used to cross-verify projections for Ovid Therapeutics. The view provides historical context for the projection set.Rule 16 Overview for current Ovid contract - Volatility Context
Rule 16 applies implied volatility to estimate a daily move of roughly 0.12% across the 2026-04-17 option cycle. With Ovid Therapeutics trading near $ 2.07, that translates to about $ 0.002549 per day in either direction.
Open Interest Snapshot: Ovid 2026-04-17 Options
Outstanding option contracts for Ovid Therapeutics are summarized through open interest, which highlights market participation.
Ovid Therapeutics Additional Predictive Modules
Most predictive techniques to examine Ovid price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Ovid using various technical indicators. When you analyze Ovid charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Ovid Therapeutics Simple Regression Price Forecast For the 13th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of Ovid Therapeutics on the next trading day is expected to be 1.72 with a mean absolute deviation of 0.13 , mean absolute percentage error of 0.03 , and the sum of the absolute errors of 7.94 .Please note that although there have been many attempts to predict Ovid Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Ovid Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Ovid Therapeutics Stock Forecast Pattern
| Backtest Ovid Therapeutics | Ovid Therapeutics Price Prediction | Research Analysis |
Ovid Therapeutics Forecasted Value
This next-day forecast for Ovid Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Ovid Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Ovid Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.3035 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.1281 |
| MAPE | Mean absolute percentage error | 0.0769 |
| SAE | Sum of the absolute errors | 7.9395 |
The mean reversion principle applied to Ovid Therapeutics' suggests that neither prolonged outperformance nor underperformance is permanent. Investors exploit this by positioning against extremes in price relative to fundamental value.
Ovid Therapeutics After-Hype Price Density Analysis
Probability distributions applied to Ovid Therapeutics price forecasting provide a more honest representation of uncertainty than single point estimates. The shape of Ovid Therapeutics' distribution - whether it is symmetric, skewed, or fat-tailed - carries important information for risk.
Next price density |
| Expected price to next headline |
Ovid Therapeutics Estimiated After-Hype Price Volatility
News-driven price analysis for Ovid Therapeutics quantifies the historical relationship between headline events and Ovid Therapeutics' short-term price response. Ovid Therapeutics' after-hype downside and upside margins for the prediction period are 0.10 and 7.72, respectively. The strength of this signal depends on the consistency of Ovid Therapeutics's past reactions to comparable news categories.
Current Value
The after-hype framework applied to Ovid Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Ovid Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Ovid Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ovid Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Ovid Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.54 | 5.69 | 0.04 | 0.00 | 7 Events | 7 Events | In 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.07 | 2.07 | 0.00 |
|
Ovid Therapeutics Hype Timeline
Ovid Therapeutics is now traded for 2.07. The company has historical hype elasticity of -0.04, and average elasticity to hype of competition of 0.0. Ovid is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at 0.54%. %. The volatility of related hype on Ovid Therapeutics is about 94833.33%, with the expected price after the next announcement by competition of 2.07. About 48.0% of the company shares are owned by institutional investors. The book value of Ovid Therapeutics was now reported as 0.63. The company recorded a loss per share of 0.5. Ovid Therapeutics had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 7 days. Historical Fundamental Analysis of Ovid Therapeutics can be used to cross-verify projections for Ovid Therapeutics. The view provides historical context for the projection set.Ovid Therapeutics Related Hype Analysis
When a direct competitor of Ovid Therapeutics experiences a significant news event, the market often re-rates Ovid Therapeutics' shares in sympathy or in contrast, depending on whether the news affects the sector broadly or competitively.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CNTX | Context Therapeutics | 0.03 | 8 per month | 3.55 | 0.34 | 10.00 | -7.05 | 24.11 | |
| MGNX | MacroGenics | -0.07 | 13 per month | 1.70 | 0.23 | 9.47 | -4.46 | 24.44 | |
| CLNN | Clene Inc | -0.24 | 9 per month | 0.00 | -0.0022 | 9.54 | -7.83 | 29.66 | |
| ORMP | Oramed Pharmaceuticals | 0.04 | 7 per month | 2.81 | 0.14 | 7.10 | -5.26 | 16.04 | |
| STTK | Shattuck Labs | 0.23 | 9 per month | 2.94 | 0.24 | 7.82 | -5.37 | 27.88 | |
| IMA | ImageneBio | 0.04 | 7 per month | 0.00 | -0.03 | 6.51 | -5.21 | 19.70 | |
| CNTB | Connect Biopharma Holdings | -0.10 | 8 per month | 5.05 | 0.08 | 8.70 | -8.00 | 23.97 | |
| IFRX | InflaRx NV | 0.01 | 7 per month | 0.00 | -0.03 | 7.00 | -7.27 | 19.51 | |
| WHWK | Whitehawk Therapeutics | 0.14 | 6 per month | 3.15 | 0.19 | 7.53 | -5.32 | 15.69 | |
| KLRS | Kalaris Therapeutics | -0.02 | 10 per month | 4.16 | 0.16 | 15.58 | -8.93 | 33.42 |
Other Forecasting Options for Ovid Therapeutics
Regardless of investment experience, understanding Ovid Therapeutics' price movement is essential for anyone considering a position in Ovid. Price charts for Ovid Stock are often filled with noise that can lead to poor investment choices if not properly filtered.Ovid Therapeutics Related Equities
The following equities are related to Ovid Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Ovid Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Ovid Therapeutics Market Strength Events
Market strength indicators for Ovid Therapeutics give investors insight into the stock's responsiveness to broader market forces. Tracking these indicators helps investors make informed timing decisions and identify periods where trading Ovid Therapeutics is likely to be most rewarding.
Ovid Therapeutics Risk Indicators
A thorough review of Ovid Therapeutics' risk indicators is an important first step in forecasting its price and managing investment exposure. This analysis helps investors determine the appropriate level of risk to accept when holding Ovid Therapeutics'.
| Mean Deviation | 4.01 | |||
| Semi Deviation | 4.22 | |||
| Standard Deviation | 5.5 | |||
| Variance | 30.23 | |||
| Downside Variance | 21.27 | |||
| Semi Variance | 17.79 | |||
| Expected Short fall | -5.08 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Ovid Therapeutics
Coverage intensity for Ovid Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Ovid Therapeutics Short Properties
Short sentiment tied to Ovid Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 70.9 M | |
| Cash And Short Term Investments | 53.1 M |
More Resources for Ovid Stock Analysis
Understanding Ovid Therapeutics typically begins with financial statements and long-term trend review. Ratio context helps frame profitability, efficiency, and growth trends for Ovid Therapeutics Stock. Outlined below are key reports that provide context for Ovid Therapeutics Stock:Historical Fundamental Analysis of Ovid Therapeutics can be used to cross-verify projections for Ovid Therapeutics. The view provides historical context for the projection set. New to investing in Ovid Stock? Start with our How to Invest in Ovid Stock guide for a step-by-step overview.Analysis related to Ovid Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Earnings Share -0.50 | Revenue Per Share | Quarterly Revenue Growth -0.24 | Return On Assets | Return On Equity |
Ovid Therapeutics market price can diverge from book value, the accounting figure shown on Ovid balance sheet. Ovid Therapeutics' market capitalization is 151.68 M. With a P/B ratio of 3.4, the market values Ovid Therapeutics well above its book equity. Enterprise value stands at 140.2 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Ovid Therapeutics' value from its trading price, which are computed with different methods. For Ovid Therapeutics, key inputs include a P/E ratio of 1.11, a P/B ratio of 3.4, ROE of -60.06%, and revenue of 566 K. The quoted price is simply the exchange level where supply meets demand.